Abstract 3143: The ADC payload PNU-159682 is highly active in a …
2024年3月22日 · Here, we introduce a unique next generation ADC platform based on Sortase-mediated antibody conjugation (SMAC-Technology) yielding in very homogenous and stable …
Here, we introduce a unique next-generation ADC platform based on Sortase-mediated antibody conjugation (SMAC-TechnologyTM), yielding in very homogenous and stable drug conjugates …
Evaluation of PNU-159682 antibody drug conjugates (ADCs)
2020年12月15日 · PNU-159682 is a highly potent secondary metabolite of nemorubicin belonging to the anthracycline class of natural products. Due to its extremely high potency and only …
ADC有效载荷（Payload）的发展及其药代动力学考量 - 知乎
蒽环类药物如阿霉素（doxorubicin）是目前骨肉瘤的一线化疗药物之一，能插入DNA双螺旋中，阻止双链分离，影响DNA复制和RNA合成。 阿霉素作为ADC有效载荷由于细胞毒性不 …
PNU-159682 | ADC毒性分子 - MCE
PNU-159682 是蒽环类新霉素的代谢产物，是一种 DNA 拓扑异构酶 II (Topo II) 抑制剂，具有出色的细胞毒性。 在ADC 合成中，PNU-159682 是一种比阿霉素更有效和耐受性更高的 ADC 细 …
PNU anthracycline payload - NBE Therapeutics
The PNU anthracycline payload is about 3 logs more potent than tubulin-targeting ADC payloads, and thus requires a highly stable linker to covalently attach it to the antibody. Using NBE …
NAV-001, a high-efficacy antibody-drug conjugate targeting
2023年5月17日 · These findings suggest that identification of HIO-refractory antibodies to be used in ADC format may improve therapeutic efficacy as observed by NAV-001 and warrants NAV …
Evaluation of PNU-159682 antibody drug conjugates (ADCs)
2020年12月15日 · Herein we seek to evaluate PNU-159682 for use in an ADC platform. Medicinal chemistry was utilized to assess structure activity relationships around both the C-14 alcohol …
有效载荷（payload）的多样性：ADC药物未来开发的关键一环
2020年，一种基于PNU-159682的新型ADC 药物NBE-002，靶向ROR1，进入了I/II期临床试验 (NCT04441099)。 另外，NBE-002还诱导了长期的免疫保护，这使得它可以成功地与免疫检 …
Advancing Antibody-Drug Conjugates (ADCs) with Novel Payloads …
2024年12月10日 · As an ADC payload, adriamycin lacks sufficient cytotoxicity (IC 50 shown in Figure 2), prompting the development of PNU-159682, which exhibits 100 times greater …